Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease

Journal of Crohn's and Colitis

Volumn 7, Issue 3, 2013, Pages 213-221

  Schreiber, S ^a   Reinisch, W ^b   Colombel, J F ^c   Sandborn, W J ^d   Hommes, D W ^e   Robinson, A M ^f   Huang, B ^f   Lomax, K G ^f   Pollack, P F ^f  

^a UNIVERSITY OF KIEL   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f ABBOTT LABORATORIES   (United States)

Author keywords

Adalimumab; Clinical remission; Disease duration; Early Crohn's disease; Safety

Indexed keywords

ADALIMUMAB; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873720197     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.05.015     Document Type: Article

References (32)

1. Cosnes J., Cattan S., Blain A., Beaugerie L., Carbonnel F., Parc R., et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002, 8:244-250.
2. Louis E., Collard A., Oger A.F., Degroote E., Aboul Nasr El, Yafi F.A., et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001, 49:777-782.
3. Pariente B., Cosnes J., Danese S., Sandborn W.J., Lewin M., Fletcher J.G., et al. Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis 2011, 17:1415-1422.
4. Thia K.T., Sandborn W.J., Harmsen W.S., Zinsmeister A.R., Loftus E.V. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010, 139:1147-1155.
5. Peyrin-Biroulet L., Loftus E.V., Colombel J.F., Sandborn W.J. Early Crohn disease: a proposed definition for use in disease-modification trials. Gut 2010, 59:141-147.
6. Castiglione F., Rispo A., Di Girolamo E., Cozzolino A., Manguso F., Grassia R., et al. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. Aliment Pharmacol Ther 2003, 18:1107-1112.
7. Hofmann A.F. The syndrome of ileal disease and the broken enterohepatic circulation: cholerhetic enteropathy. Gastroenterology 1967, 52:752-757.
8. Hofmann A.F., Poley J.R. Role of bile acid malabsorption in pathogenesis of diarrhea and steatorrhea in patients with ileal resection. I. Response to cholestyramine or replacement of dietary long chain triglyceride by medium chain triglyceride. Gastroenterology 1972, 62:918-934.
9. Cosnes J., de Parades V., Carbonnel F., Beaugerie L., Ngo Y., Gendre J.P., et al. Classification of the sequelae of bowel resection for Crohn's disease. Br J Surg 1994, 81:1627-1631.
10. Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593.
11. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., van Vollenhoven R., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54:26-37.
12. Genovese M.C., Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002, 46:1443-1450.
13. St Clair E.W., van der Heijde D.M., Smolen J.S., Maini R.N., Bathon J.M., Emery P., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004, 50:3432-3443.
14. Schreiber S., Colombel J.F., Bloomfield R., Nikolaus S., Scholmerich J., Panes J., et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010, 105:1574-1582.
15. Schreiber S., Targan S. Efficacy of natalizumab in Crohn's patients with disease duration less than three years. Gastroenterology 2007, 132:A509.
16. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
17. D'Haens G., Baert F., van Assche G., Caenepeel P., Vergauwe P., Tuynman H., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
18. Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009, 58:492-500.
19. Vermeire S., Louis E., Carbonez A., Van Assche G., Noman M., Belaiche J., et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002, 97:2357-2363.
20. D'Haens G.R., Fedorak R., Lemann M., Feagan B.G., Kamm M.A., Cosnes J., et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis 2009, 15:1599-1604.
21. Van Assche G., Vermeire S., Rutgeerts P. The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol 2010, 7:79-85.
22. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
23. Panaccione R., Colombel J.F., Sandborn W.J., Rutgeerts P., D'Haens G.R., Robinson A.M., et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther 2010, 31:1296-1309.
24. Kamm M.A., Hanauer S.B., Panaccione R., Colombel J.F., Sandborn W.J., Pollack P.F., et al. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther 2011, 34:306-317.
25. Sandborn W.J., Abreu M.T., D'Haens G.R., Colombel J.-F., Vermeire S., Mitchev K., et al. Predictors of response and remission to certolizumab pegol in patients with Crohn's disease: Data from the WELCOME Study. Gastroenterology 2010, 138:S-164.
26. Hanauer S., Schreiber S., Thompsen O. Analysis of predictors of response maintenance to certolizumab pegol in patients with active Crohn's disease: data from PRECiSE 2. J Crohns Colitis 2008, 2:6.
27. Hanauer S.B., Panes J., Colombel J.F., Bloomfield R., Schreiber S., Sandborn W.J. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther 2010, 32:384-393.
28. Peyrin-Biroulet L., Loftus E.V., Colombel J.F., Sandborn W.J. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010, 105:289-297.
29. Lichtenstein G.R., Feagan B.G., Cohen R.D., Salzberg B.A., Diamond R.H., Chen D.M., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4:621-630.
30. Akobeng A.K., Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database Syst Rev 2005, Issue 1. Art. No.: CD003715. http://dx.doi.org/10.1002/14651858.CD003715.pub2.
31. Thomsen O.O., Cortot A., Jewell D., Wright J.P., Winter T., Veloso F.T., et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998, 339:370-374.
32. Rutgeerts P.J. Review article: the limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther 2001, 15:1515-1525.